drugset / Trial / NCT01410214
Erlotinib Versus Vinorelbine/Cisplatin as Adjuvant Treatment in Stage IIIA NSCLC Patients With EGFR Mutations
Phase 2
Unknown
80 enrolled
Chinese Lung Cancer Surgical Group
Chinese PLA General Hospital · collabFudan University · collabHebei Medical University Fourth Hospital · collabPeking University Cancer Hospital & Institute · collabQingdao University · collabSun Yat-sen University · collabThe First Affiliated Hospital of Soochow University · collabThe Second Affiliated Hospital of Harbin Medical University · collabThe Second People's Hospital of Sichuan · collabTianjin Medical University Cancer Institute and Hospital · collabZhejiang Cancer Hospital · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the effect and safety of erlotinib versus NVB plus cisplatin (NP) as adjuvant treatment in patients with stage IIIA NSCLC after complete resection with EGFR activating mutations and to explore a new treatment strategy for this subset.
Timeline
- Start
- 2011-05
- Primary completion
- 2015-07
- Completion
- 2017-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cisplatin | Other / unclassified | 25 mg/m2 | Intravenous |
| Subject | Erlotinib | Small molecule | 150 mg | Oral |
| Comparator | Vinorelbine | Small molecule | 25 mg/m2 | Intravenous |